Pembrolizumab plus olaparib vs enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer who experienced progression on chemotherapy: phase 3 KEYLYNK-010 study

被引：0
|
作者：
Yu, Evan [1 ]
Park, Se Hoon [2 ]
Huang, Yi-Hsiu [3 ]
Bennamoun, Mostefa [4 ]
Xu, Lu [5 ]
Kim, Jeri [5 ]
Antonarakis, Emmanuel [6 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Samsung Med Ctr, Seoul, South Korea
[3] Taipei Vet Gen Hosp, Taipei, Taiwan
[4] Inst Mutualiste Montsouris, Paris, France
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P390
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Abiraterone, Olaparib, or Abiraterone plus Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
    Hussain, Maha
    Kocherginsky, Masha
    Agarwal, Neeraj
    Adra, Nabil
    Zhang, Jingsong
    Paller, Channing J.
    Picus, Joel
    Reichert, Zachery R.
    Szmulewitz, Russell Z.
    Tagawa, Scott T.
    Kuzel, Timothy M.
    Bazzi, Latifa A.
    Daignault-Newton, Stephanie
    Whang, Young E.
    Dreicer, Robert
    Stephenson, Ryan D.
    Rettig, Matthew B.
    Shevrin, Daniel
    Gerke, Travis
    Chinnaiyan, Arul M.
    Antonarakis, Emmanuel S.
    CLINICAL CANCER RESEARCH, 2024, 30 (19) : 4318 - 4328
  • [32] KEYNOTE-641: Phase III study of pembrolizumab (pembro) plus enzalutamide for metastatic castration-resistant prostate cancer (mCRPC)
    Graff, J. N.
    Burgents, J.
    Liang, L. W.
    Stenzl, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] PHASE 3 TRIAL OF PEMBROLIZUMAB AND ENZALUTAMIDE VERSUS ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-641)
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A210 - A210
  • [34] Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial
    Armstrong, Andrew J.
    Clarke, Noel
    Oya, Mototsugu
    Procopio, Giuseppe
    de Menezes, Juliana
    Guedes, Joao Daniel
    Ghatalia, Pooja
    Nole, Franco
    Din, Omar
    Spiegelhalder, Philipp
    Mincik, Ivan
    van Alphen, Robbert
    Lumen, Nicolaas
    Hosius, Christian
    Zhou, Diansong
    Barker, Laura
    Dujka, Melanie
    Saad, Fred
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (02): : 292 - 296
  • [35] Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study
    Maughan, Benjamin L.
    Luber, Brandon
    Nadal, Rosa
    Antonarakis, Emmanuel S.
    PROSTATE, 2017, 77 (01): : 33 - 40
  • [36] Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Salem, S.
    Komisarenko, M.
    Timilshina, N.
    Martin, L.
    Grewal, R.
    Alibhai, S.
    Finelli, A.
    CLINICAL ONCOLOGY, 2017, 29 (09) : 601 - 608
  • [37] Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study
    Azuma, Takeshi
    PROSTATE, 2018, 78 (04): : 278 - 278
  • [38] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1032 - 1040
  • [39] Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer
    Avxentyev, N. A.
    Frolov, M. Yu
    Makarova, Yu, V
    ONKOUROLOGIYA, 2019, 15 (02): : 86 - 99
  • [40] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Tagawa, Scott T.
    Ramaswamy, Krishnan
    Huang, Ahong
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Sandin, Rickard
    Lechpammer, Stanislav
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1032 - 1040
12345